Scientists test combo attack to boost immune system against pancreatic cancer
NCT ID NCT03727880
Summary
This study tested whether adding one or two experimental immunotherapy drugs to standard chemotherapy, given both before and after surgery, could better control high-risk pancreatic cancer. It involved 28 adults with surgically removable pancreatic cancer who had not received prior treatment. The goal was to see if these drugs could help the body's immune system fight the cancer more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samuel Oschin Cancer Center at Cedars-Sinai
Los Angeles, California, 90048, United States
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
-
The University of Texas Health Science Center San Antonio
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.